BI/Lilly Engel net reaches phase 3 clinical end.

Heart failure is an aggressive, debilitating and potentially fatal disease.
is a widespread disease affecting 60 million people around the world, and the number of patients is expected to increase as the population ages.
heart failure is common in people with diabetes, however, about half of heart failure patients do not have diabetes.
risk of death in patients with heart failure increases with each hospitalization.
(HFrEF), which reduces the blood score, occurs when the heart muscle does not contract effectively and pumps less blood into the body than a functioning heart.
Ngle net is a daily oral, highly selective sodium glucose co-transport protein 2 (SGLT2) inhibitor, in patients with type 2 diabetes with high blood sugar levels, engel net inhibition SGLT2 can prevent sugar from being re-absorbed by the kidneys, allowing more sugar to be excreted from the urine.
addition, Ingle Net prevents the re-absorption of salt, thereby increasing the excretion of salt in the body and reducing the fluid load on the body's vascular system.
of sugar, salt, and water in the body induced by engele may help reduce cardiovascular death.
phase 3 clinical trial, called EMPEROR-Reduced, tested the efficacy and safety of Engelef in patients with type 2 diabetes and those without type 2 diabetes.
end point of the trial is the time required for cardiovascular death or hospitalization for the first time due to heart failure.
results of this trial are expected to be presented on August 29th at the 2020 Meeting of the European Society of Cardiology (ESC).
same time, Engele is being tested in a Phase 3 clinical trial called EMPEROR-Preserved to treat adult patients with heart failure who have a blood test score retention.
"Heart failure is a common but very serious chronic cardiovascular disease that causes substantial disability and threatens the lives of millions of people around the world," said Dr. Milton Packer of Baylor University Medical Center, who led the EMPEROR Clinical Program.
results from the EMPEROR-Reduced trial suggest that SGLT2 inhibitors have the potential to become a new standard of care for the disease, which will be a meaningful complement to established treatments.
" Lilly and Grigg Ingham are expected to file regulatory applications in 2020.
resources: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved July 30, 2020, from original title: Express . BI/Lilly Engele net reached phase 3 clinical endpoint, significantly reducing the risk of cardiovascular death and hospitalization of heart failure in patients with heart failure.